Conventional chemotherapy may improve advanced NSCLC survival

This article originally appeared here.
Share this content:
Conventional Chemo May Be Better for Some Advanced NSCLC
Conventional Chemo May Be Better for Some Advanced NSCLC

(HealthDay News) -- For patients with non-small-cell lung cancer (NSCLC) and wild-type (WT) epidermal growth factor receptor (EGFR) mutations, conventional chemotherapy improves progression-free survival (PFS) better than first-generation EGFR tyrosine kinase inhibitors (TKIs), according to research published in the April 9 issue of the Journal of the American Medical Association.

June-Koo Lee, M.D., from the Seoul National University Hospital in South Korea, and colleagues conducted a literature review to identify randomized controlled trials comparing EGFR TKI with conventional chemotherapy in patients with advanced NSCLC.

Based on 11 trials (1,605 patients with WT EGFR tumors), the researchers found that chemotherapy was associated with improvement of PFS, compared with TKI (hazard ratio [HR] for TKI, 1.41). Line of treatment (first-line versus second- or later-line), experimental drug, dominant ethnicity, or EGFR mutation analysis method did not differ significantly between the groups. There was a significant PFS benefit with chemotherapy (HR for TKI, 1.84) in trials using more sensitive platforms than direct sequencing. Improvement in PFS associated with chemotherapy was also significant in second- or later-line trials (HR, 1.34).

"Among patients with advanced NSCLC harboring WT EGFR, conventional chemotherapy, compared with first-generation EGFR TKI, was associated with improvement in PFS but not overall survival," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs